Lupin says USFDA warning on Goa and Pithampur facilities are resolved
“We are pleased to be informed by the USFDA that we have addressed the concerns through our corrective actions related to the November 2017 Warning Letter," said Nilesh Gupta, MD of Lupin. «We are committed to being compliant with good manufacturing practices, and to uphold global quality standards and ensuring the quality of our products,” Gupta added.
ET on early this month reported that Lupin's establishment inspection report (EIR) from the USFDA with a voluntary action indicated (VAI) status for its Pithampur Unit-2 facility in Madhya Pradesh will pave the way for possible lifting of warning letters on the facility. Shares of Lupin rose 4.09% to close at Rs 980.05 on BSE on Thursday, while the benchmark Sensex declined 0.66% to end 66,266.82 points.
. Read more on economictimes.indiatimes.com
